Zobrazeno 1 - 10
of 81
pro vyhledávání: '"F. Pineau-Vincent"'
Publikováno v:
Transfusion Clinique et Biologique. 28:191-193
We report the case of a 43-years-old Turkish man with acquired deficiency of factor V (FV) diagnosed in a usual screening before a (recto) colonoscopy. In the biologic explorations, activated partial prothrombin time (APTT) was abnormally high and pr
Publikováno v:
Transfusion Clinique et Biologique. 26:356-358
We report the case of a French woman with acquired von Willebrand syndrome who presents recurrent subarachnoid and intra-cerebral hemorrhage since 2012. She had no family or personal bleeding history. In the biologic explorations, APTT was abnormally
Autor:
E. Hergon, S. Moron, J.F. Quaranta, J. Beauvais, F. Pineau-Vincent, N. Canivet, M.L. Pibarot, Philippe Rouger, V. Vannier
Publikováno v:
Transfusion Clinique et Biologique. 6:275-284
Risk management in the hospital, which is one of the referentiels of the ANAES accreditation manual, may be considered on two levels. Firstly, risk management may be approached globally, in the same way as it is tackled in the accreditation process.
Autor:
M Coudé, F Pineau-Vincent
Publikováno v:
Immuno-analyse & Biologie Spécialisée. 19:177-179
Resume En 1996, le groupe de Bertina a identifie au niveau du gene de la prothrombine, situe sur le chromosome 11, une mutation associee a une augmentation du facteur II. La mutation G20210A appelee egalement mutation Leiden est impliquee dans la mal
Autor:
V Horvais, M Pennetier, G Chapelle, A Athouel, S Bauer, V Cogulet, C Lebert, M Clerc, I Vincent, Y Poirier, N Le Gall, V Pacaud, S Daubie, S Orhon-Ménard, M Gaumé, P Jaccard, M Haudot-Lépine, J Teil, J Huaut-Quentel, B Lassère, M Kuzzay, M Roy, A Gaudy, C Baubri, A Courtois, I Baudin Jacquemin-Aubry, N Ripoll, P Chauvet, B Pan-Petesch, L Ardillon, B Guillet, P Beurrier, F Pineau-Vincent, L Macchi, L Ferrand, M Trossaërt, null BERHLINGO Group
Publikováno v:
Value in Health. 19:A586
Publikováno v:
Annales d'Endocrinologie. 77:509
Le pembrolizumab (anticorps monoclonal anti-PD1) et l’ipilimumab (anticorps anti-CTLA4) sont des immunotherapies prometteuses dans le melanome non resecable ou metastatique. Ils potentialisent l’activation, la proliferation et l’infiltration de
Publikováno v:
Annales de biologie clinique. 63(6)
[Risk management program in a health facility using a project approach: transfusion risk management]
Autor:
E, Hergon, J F, Quaranta, N, Canivet, S, Moron, F, Pineau-Vincent, V, Vannier, J, Beauvais, M L, Pibarot, P, Rouger
Publikováno v:
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine. 6(5)
Risk management in the hospital, which is one of the referentiels of the ANAES accreditation manual, may be considered on two levels. Firstly, risk management may be approached globally, in the same way as it is tackled in the accreditation process.
Publikováno v:
Vox sanguinis. 70(2)
The discovery of natural Gerbich antigen (anti-Ge2) in the serum of propositus prompted us to study his red blood cells (RBCs) by using monoclonal antibodies (mAbs) directed against glycophorin (GP) C and GPD. An mAb directed against the Ge4 antigen
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.